As global markets continue to experience fluctuations, with U.S. stocks reaching record highs amid optimism for softer tariffs and AI-related investments, investors are increasingly focused on identifying opportunities that may be trading below their intrinsic value. In such a climate, finding stocks that are potentially undervalued can be particularly appealing, as they offer the possibility of capitalizing on market inefficiencies while navigating the evolving economic landscape. Top 10 Undervalued Stocks Based On Cash Flows Name Current Price Fair Value (Est) Discount (Est) Sichuan Injet Electric (SZSE:300820) CN¥50.58 CN¥100.77 49.8% GlobalData (AIM:DATA) £1.78 £3.56 49.9% Fudo Tetra (TSE:1813) ¥2192.00 ¥4357.83 49.7% J Trust (TSE:8508) ¥520.00 ¥1039.92 50% Bufab (OM:BUFAB) SEK464.20 SEK926.28 49.9% Greenworks (Jiangsu) (SZSE:301260) CN¥13.83 CN¥27.64 50% IDP Education (ASX:IEL) A$13.17 A$26.31 49.9% Allied Blenders and Distillers (NSEI:ABDL) ₹394.40 ₹787.12 49.9% Condor Energies (TSX:CDR) CA$1.83 CA$3.64 49.7% Vista Group International (NZSE:VGL) NZ$3.24 NZ$6.15 47.3% Click here to see the full list of 904 stocks from our Undervalued Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Salvatore Ferragamo Overview: Salvatore Ferragamo S.p.A. is a luxury goods company that designs, produces, and sells products for men and women across Europe, North America, Japan, the Asia Pacific, and Central and South America with a market cap of approximately €1.17 billion. Operations: The company's revenue primarily comes from its footwear segment, which generated €1.08 billion. Estimated Discount To Fair Value: 35.3% Salvatore Ferragamo is trading at €7.28, significantly below its estimated fair value of €11.24, highlighting its undervaluation based on discounted cash flow analysis. Despite recent volatility and a decline in profit margins to 0.9%, earnings are expected to grow substantially at 38.1% annually, surpassing the Italian market's growth rate of 6.7%. However, future return on equity remains low at a forecasted 4.8% in three years. According our earnings growth report, there's an indication that Salvatore Ferragamo might be ready to expand. Click here and access our complete balance sheet health report to understand the dynamics of Salvatore Ferragamo.BIT:SFER Discounted Cash Flow as at Jan 2025 Haisco Pharmaceutical Group Overview: Haisco Pharmaceutical Group Co., Ltd. engages in the research, development, manufacturing, and sale of pharmaceuticals in China with a market cap of CN¥35.37 billion. Operations: The company's revenue is primarily derived from its activities in researching, developing, manufacturing, and selling pharmaceuticals within China. Story Continues Estimated Discount To Fair Value: 42.7% Haisco Pharmaceutical Group, trading at CN¥31.89, is undervalued with an estimated fair value of CN¥55.7. Earnings are projected to grow significantly at 35.7% annually, outpacing the Chinese market's 25% growth rate, while revenue is expected to increase by 23% per year. Despite a low future return on equity forecast of 16.1%, its current valuation and growth prospects make it an attractive consideration for cash flow-focused investors. Recent dividend affirmations reflect stable profit distribution plans. Upon reviewing our latest growth report, Haisco Pharmaceutical Group's projected financial performance appears quite optimistic. Click to explore a detailed breakdown of our findings in Haisco Pharmaceutical Group's balance sheet health report.SZSE:002653 Discounted Cash Flow as at Jan 2025 DTS Overview: DTS Corporation offers systems integration services in Japan and has a market cap of ¥175.43 billion. Operations: The company's revenue segments include Platform & Services at ¥29.38 billion, Business & Solutions at ¥49.81 billion, and Technology & Solutions at ¥42.66 billion. Estimated Discount To Fair Value: 11.7% DTS is trading at ¥4,245, below its estimated fair value of ¥4,809.31. Revenue growth is forecast at 6.7% annually, surpassing the JP market's 4.3%. Earnings are expected to grow faster than the market at 12.3% per year but not significantly high. Recent share buybacks totaling ¥5,999.83 million aim to enhance shareholder returns and capital efficiency. The stock's undervaluation and growth potential offer a compelling case for cash flow-focused investors despite an unstable dividend history. Our expertly prepared growth report on DTS implies its future financial outlook may be stronger than recent results. Navigate through the intricacies of DTS with our comprehensive financial health report here.TSE:9682 Discounted Cash Flow as at Jan 2025 Summing It All Up Unlock our comprehensive list of 904 Undervalued Stocks Based On Cash Flows by clicking here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BIT:SFER SZSE:002653 and TSE:9682. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
Three Stocks That Could Be Trading Below Their Estimated Intrinsic Value
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...